LARP7

Across TCGA pan-cancer cohorts, LARP7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LARP7 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LARP7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LARP7 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where LARP7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.217	0.909	<.001	22	view →
PDAC	OS	Median	All	0.368	0.596	.002	22	view →
HNSC	DFS	Median	III,IV	0.521	0.740	.020	15	view →
CCRCC	DFS	Quartile	III,IV	0.811	1.000	.029	5	view →
LSCC	OS	Tertile	III,IV	0.521	0.918	.026	5	view →
GBM	OS	Median	All	0.520	0.280	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LARP7–LUAD (DFS)

Open the LUAD breakdown →